DNA Medicine Institute Awarded IDIQ Contract with $151B SHIELD
The DNA Medicine Institute, Inc. (DMI) is pleased to announce it was awarded a contract for the Missile Defense Agency Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract with a ceiling of $151B. This contract encompasses a broad range of work areas that allows for the rapid delivery of innovative capabilities to the warfighter with increased speed and agility.
NASA Launches rHEALTH Blood Analyzer to Space
Bedford, MA, February 19, 2022. rHEALTH, announced today that NASA has successfully launched its rHEALTH ONE blood analyzer to space on NASA Commercial Resupply Mission NG-17. The rHEALTH ONE was carried to the International Space Station (ISS) via the NG-17 Cygnus spacecraft, launched by a Northrop Grumman Antares Rocket.
rHEALTH’s FVIII Point-of-Care Device Awarded $1.5M Direct-to-Phase II Grant from the NIH
rHEALTH’s innovative fingerstick-based diagnostic platform receives NIH support to monitor FVIII and emicizumab levels, improving access to testing and patient care worldwide.
rHEALTH Attains ISO 13485 Certification
rHEALTH attains globally recognized medical device quality certification and expands its Bedford facility to meet growing commercial and diagnostic demands.
DMI and COVID-19
rHEALTH remains dedicated to delivering accessible, accurate diagnostic solutions to support patients, communities, and partners, even in times of uncertainty.
rHEALTH Technology Granted US Patent for Small Volume Blood Handling in Point-of-Care Devices
rHEALTH LLC and DNA Medicine Institute announce USPTO Patent No. 10,449,537, enabling precise manipulation of tiny blood samples for accurate point-of-care testing at home, clinics, and beyond.
rHEALTH Nanostrips, Vitals Device, and Fluidics Module to Receive U.S. Patent Protection
rHEALTH LLC and DNA Medicine Institute announce USPTO patent approvals for Nanostrips, SKYE Sensor, and Fluidics Module, strengthening their “Diagnose Yourself, Anywhere™” technology.
rHEALTH ONE Oral Presentation at CYTO 2019!
Dr. Eugene Chan to present the rHEALTH ONE, a 1.5 kg microvolume cytometer, at CYTO 2019 in Vancouver, highlighting its precision, multiplexed sensitivity, and point-of-care potential.
Abstracts for rHEALTH’s Factor VIII and Platelet Tests Accepted for Poster and Oral Presentations at Upcoming AACC 2019 Meeting
rHEALTH LLC and DNA Medicine Institute announce peer-reviewed acceptance of two abstracts at the 2019 AACC Annual Scientific Meeting, highlighting advanced point-of-care testing for FVIII and platelet counts.
rHEALTH ONE Blood Analyzers Delivered to NASA for International Space Station
rHEALTH LLC and DNA Medicine Institute announce delivery of the rHEALTH ONE blood analyzer to NASA for spaceflight qualification, marking a major milestone in point-of-care diagnostics for astronauts and terrestrial applications.
rHEALTH FVIII Solution to be Presented at WFH’s 11th Global Forum
Dr. Eugene Y. Chan will showcase rHEALTH’s patent-pending FVIII point-of-care solution, designed for accurate home and in-office measurement of FVIII levels, including for gene therapy and long-acting treatments.
rHEALTH Technology Awarded in NASA’s Civilian Commercialization Readiness Pilot Program (CCRPP)
CAMBRIDGE, Mass., Aug. 20, 2018 — DNA Medicine Institute, Inc., and its affiliate rHEALTH LLC, a digital health solutions company, today announced that the rHEALTH technology is a subject of NASA’s Civilian Commercial Readiness Pilot Program (CCRPP).